Skip to main content

Table 3 Stratified analysis of the relationships between AKAP6 polymorphisms and glioma risk

From: Impact of AKAP6 polymorphisms on Glioma susceptibility and prognosis

SNP ID

Models

OR (95%CI)

p

OR (95%CI)

p

Age

 

≤ 40

>  40

rs2239647

Allele

1.20 (0.92–1.57)

0.171

1.17 (0.89–1.54)

0.273

Homozygote(AA)

1.68 (0.87–3.24)

0.123

2.60 (1.23–5.51)

0.012

Heterozygote(CA)

1.19 (0.83–1.71)

0.347

0.82 (0.57–1.18)

0.281

Dominant

1.26 (0.89–1.78)

0.187

0.98 (0.70–1.39)

0.925

Recessive

1.56 (0.82–2.95)

0.174

2.83 (1.36–5.89)

0.006

Additive

1.25 (0.95–1.64)

0.107

1.17 (0.89–1.54)

0.254

Gender

 

Male

Female

rs2145587

Allele

1.06 (0.84–1.33)

0.633

1.28 (0.98–1.68)

0.065

Homozygote(AA)

1.16 (0.71–1.90)

0.553

1.40 (0.77–2.53)

0.266

Heterozygote(CA)

1.00 (0.70–1.43)

0.998

1.62 (1.10–2.38)

0.016

Dominant

1.04 (0.74–1.45)

0.837

1.57 (1.08–2.27)

0.017

Recessive

1.16 (0.74–1.82)

0.514

1.08 (0.62–1.87)

0.794

Additive

1.06 (0.84–1.34)

0.625

1.30 (0.99–1.71)

0.060

rs2239647

Allele

1.22 (0.94–1.58)

0.130

1.14 (0.86–1.51)

0.374

Homozygote(AA)

2.42 (1.21–4.87)

0.003

1.48 (0.75–2.89)

0.256

Heterozygote(GA)

0.94 (0.67–1.32)

0.714

1.02 (0.70–1.50)

0.909

Dominant

1.08 (0.78–1.50)

0.627

1.09 (0.76–1.57)

0.630

Recessive

2.49 (1.25–4.93)

0.009

1.46 (0.76–2.80)

0.253

Additive

1.22 (0.94–1.57)

0.135

1.13 (0.86–1.50)

0.384

Classification

 

Astroglioma patients VS Healthy controls

rs2239647

Allele

1.18 (0.96–1.45)

0.106

  

Homozygote(AA)

1.90 (1.15–3.15)

0.012

  

Heterozygote(CA)

0.98 (0.75–1.29)

0.900

  

Dominant

1.10 (0.85–1.42)

0.485

  

Recessive

1.92 (1.17–3.13)

0.009

  

Additive

1.19 (0.97–1.45)

0.098

  
  1. SNP single nucleotide polymorphism, OR odds ratio, 95% CI 95% confidence interval
  2. p values were calculated by logistic regression analysis with adjustments for age and gender
  3. Bold values indicate statistical significance (p < 0.05)